Trends in Financial Access to Prescription Drugs among Cancer Survivors

Journal of the National Cancer Institute

Volumn 110, Issue 2, 2018, Pages 216-219

  Gonzales, Felisa ^a   Zheng, Zhiyuan ^b,c   Robin Yabroff, K ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRESCRIPTION DRUG;

ADULT; AGED; ARTICLE; CANCER SURVIVOR; DRUG COST; FEMALE; HEALTH INSURANCE; HUMAN; MALE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; ADOLESCENT; AGE; ECONOMICS; HEALTH CARE DELIVERY; MIDDLE AGED; NEOPLASMS; STATISTICS AND NUMERICAL DATA; SURVIVOR; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; NEOPLASMS; PRESCRIPTION DRUGS; SURVIVORS; UNITED STATES; YOUNG ADULT;

EID: 85029794168     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djx164     Document Type: Article

References (30)

1. Office of the Assistant Secretary for Planning and Evaluation. Observations on trends in prescription drug spending. Washington, DC: Office of the Assistant Secretary for Planning and Evaluation; 2016. https://aspe.hhs.gov/pdf-report/observations-trends-prescription-drug-spending. Accessed December 7, 2016.
2. Cox C, Kamal R, Jankiewicz A, et al. Recent trends in prescription drug costs. JAMA. 2016;315(13):1326-1326.
3. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: Justum Pretium-the just price J Clin Oncol. 2013;31(28):3600-3604.
4. Yabroff KR, Dowling EC, Guy GP Jr, et al. Financial hardship associated with cancer in the United States: Findings from a population-based sample of adult cancer survivors J Clin Oncol. 2016;34(3):259-267.
5. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119(6):1257-1265.
6. Guy GP, Jr., Yabroff KR, Ekwueme DU, et al. Healthcare expenditure burden among non-elderly cancer survivors, 2008-2012. Am J Prev Med. 2015;49(6 suppl 5):S489-S497.
7. Narang AK, Nicholas LH. Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer. JAMA Oncol. 2016;3(6):757-765.
8. Altice CK, Banegas MP, Tucker-Seeley RD, et al. Financial hardships experienced by cancer survivors: A systematic review. J Natl Cancer Inst. 2017;109(2): djw205.
9. Davidoff AJ, Hu X, Zheng Z, et al. Early impact of the Affordable Care Act (ACA) on financial worry. Poster presented at the ASCO Quality Care Symposium; February 2016; Phoenix, AZ.
10. Banegas MP, Guy GP Jr, de Moor JS, et al. For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff (Millwood). 2016;35(1):54-61.
11. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Afjf(Milliuood). 2013;32(6):1143-1152.
12. Zafar SY, McNeil RB, Thomas CM, et al. Population-based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study. J Oncol Pract. 2015;11(2):145-150.
13. Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283-289.
14. Zafar SY, Peppercorn JM, Schrag D, et al.The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist. 2013;18(4):381-390.
15. Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710-3717.
16. Winn AN, Keating NL, Dusetzina SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol. 2016;34(36):4323-4328.
17. Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-311.
18. IS. Hershman DL, Tsui J, Meyer J, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst. 2014;106(11):dju319.
19. Neugut AI, Subar M, Wilde ET, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol. 2011;29(18):2534-2542.
20. Wu EQ, Johnson S, Beaulieu N, et al. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients. Curr Med Res Opin. 2010;26(1):61-69.
21. Perrone F, Jommi C, Di Maio M, et al. The association of financial difficulties with clinical outcomes in cancer patients: Secondary analysis of 16 academic prospective clinical trials conducted in Italy. Ann Oncol. 2016;27(12): 2224-2229.
22. Kesselheim AS, Avom J, Sarpatwari A. The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA. 2016;316(8): 85S-S71.
23. Kaiser health tracking poll. September 2016. http://kff.org/health-costs/re port/kaiser-health-tracking-poll-september-2016/. Accessed September 29, 2016.
24. Davidoff AJ, Hill SC, Bernard D, et al. The Affordable Care Act and expanded insurance eligibility among nonelderly adult cancer survivors. J Natl Cancer Inst. 2015;107(9):djvlSl.
25. Graubard BI, Kom EL. Predictive margins with survey data. Biometrics. 1999; 55(2):652-659.
26. Dusetzina SB. Share of specialty drugs in commercial plans nearly quadrupled, 2003-14. Health Aff (Millwood). 2016;35(7):1241-1246.
27. Express scripts: Drug trend report. http://lab.express-scripts.com/lab/drug-trend-report. Accessed December 23, 2016.
28. de Moor JS, Mariotto AB, Parry C, et al. Cancer survivors in the United States: Prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev. 2013;22(4):561-570.
29. Briesacher BA, Gurwitz JH, Soumerai SB. Patients at-risk for cost-related medication nonadherence: A review of the literature. J Gen Intern Med. 2007;22(6): 864-871.
30. Mulcahy AW, Eibner C, Finegold K. Gaining coverage through Medicaid or private insurance increased prescription use and lowered out-of-pocket spending. Health Aff(Millwood). 2016;35(9):1725-1733.